OS Therapies unit OS Animal Health gets USDA feedback on conditional licensure path for OST-HER2 in canine osteosarcoma

PUBT · 1d ago
OS Therapies unit OS Animal Health gets USDA feedback on conditional licensure path for OST-HER2 in canine osteosarcoma
  • OS Therapies’ animal health unit, OS Animal Health, received USDA feedback on the regulatory pathway for OST-HER2 in canine osteosarcoma.
  • Guidance covered clinical efficacy, safety, non-clinical requirements, and CMC ahead of a planned conditional licensure request.
  • OS Animal Health targets a 2027 U.S. commercial launch; expects additional studies to support full USDA licensure.
  • OS Therapies is weighing strategic or capital alternatives to monetize OS Animal Health for shareholder benefit.
  • OS Animal Health plans a Q4 2026 crowdfunding to broaden ownership ahead of a potential U.S. exchange listing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610070830NEWSFILECNPR____20261007_317856_1) on October 07, 2026, and is solely responsible for the information contained therein.